A detailed history of Fortitude Family Office, LLC transactions in Nektar Therapeutics stock. As of the latest transaction made, Fortitude Family Office, LLC holds 21 shares of NKTR stock, worth $1,318. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21
Holding current value
$1,318
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 17, 2025

BUY
$21.68 - $60.33 $455 - $1,266
21 New
21 $1.2 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $11.8B
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Fortitude Family Office, LLC Portfolio

Follow Fortitude Family Office, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fortitude Family Office, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fortitude Family Office, LLC with notifications on news.